The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...
Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...
A new drug developed to slow the progression of Alzheimer’s disease has been turned down for approval by the European drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback